- Home
- LNG vs XGN Comparison
LNG vs XGN Comparison
Compare LNG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNG
- XGN
- Stock Information
- Founded
- LNG 1983
- XGN 2002
- Country
- LNG United States
- XGN United States
- Employees
- LNG N/A
- XGN N/A
- Industry
- LNG Oil/Gas Transmission
- XGN Medical Specialities
- Sector
- LNG Utilities
- XGN Health Care
- Exchange
- LNG Nasdaq
- XGN Nasdaq
- Market Cap
- LNG 53.9B
- XGN 138.3M
- IPO Year
- LNG 1997
- XGN 2019
- Fundamental
- Price
- LNG $233.76
- XGN $6.98
- Analyst Decision
- LNG Strong Buy
- XGN Strong Buy
- Analyst Count
- LNG 14
- XGN 2
- Target Price
- LNG $253.64
- XGN $7.50
- AVG Volume (30 Days)
- LNG 1.6M
- XGN 253.4K
- Earning Date
- LNG 08-07-2025
- XGN 08-04-2025
- Dividend Yield
- LNG 0.85%
- XGN N/A
- EPS Growth
- LNG N/A
- XGN N/A
- EPS
- LNG 13.71
- XGN N/A
- Revenue
- LNG $16,739,000,000.00
- XGN $56,724,000.00
- Revenue This Year
- LNG $33.47
- XGN $18.92
- Revenue Next Year
- LNG $12.47
- XGN $14.78
- P/E Ratio
- LNG $17.15
- XGN N/A
- Revenue Growth
- LNG N/A
- XGN 1.78
- 52 Week Low
- LNG $167.66
- XGN $1.78
- 52 Week High
- LNG $257.65
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- LNG 46.11
- XGN 52.18
- Support Level
- LNG $235.61
- XGN $6.82
- Resistance Level
- LNG $241.48
- XGN $7.15
- Average True Range (ATR)
- LNG 5.98
- XGN 0.36
- MACD
- LNG -0.70
- XGN -0.06
- Stochastic Oscillator
- LNG 26.49
- XGN 37.07
About LNG Cheniere Energy Inc.
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.